FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study.
Humans
Antigens, Neoplasm
Biomarkers, Tumor
/ metabolism
Coloring Agents
Lymphatic Metastasis
/ diagnosis
MART-1 Antigen
Melanoma
/ pathology
Nevus
/ pathology
Nevus, Pigmented
/ pathology
Retrospective Studies
Sentinel Lymph Node Biopsy
Skin Neoplasms
/ pathology
Proto-Oncogene Protein c-fli-1
Melanoma, Cutaneous Malignant
FLI-1
FLI-1/Melan-A
PRAME
metastatic melanoma
nodal nevus
Journal
Journal of cutaneous pathology
ISSN: 1600-0560
Titre abrégé: J Cutan Pathol
Pays: United States
ID NLM: 0425124
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
13
11
2022
received:
04
04
2022
accepted:
28
11
2022
pubmed:
2
12
2022
medline:
18
2
2023
entrez:
1
12
2022
Statut:
ppublish
Résumé
Melanocytic nevi existing in lymph nodes create a diagnostic challenge by mimicking metastases. PReferentially expressed Antigen in MElanoma (PRAME) immunohistochemical (IHC) stain can differentiate one from another. FLI-1 IHC expression has been shown in malignant melanoma with variable sensitivity while melanocytic nevi were reported to be negative. We hypothesized that FLI-1/Melan-A dual IHC staining may be used in the distinction of metastatic melanoma from nodal nevi and can be an alternative and/or complementary to PRAME. In this study, we examined 13 lymph nodes with metastatic melanoma and 13 lymph nodes with benign deposits. We stained all of the lymph nodes with FLI-1, FLI-1/Melan-A dual, and PRAME IHC stains. In addition, we stained paired skin samples of the metastatic lymph nodes with FLI-1 and PRAME. In primary cutaneous melanomas, 11 of 13 were positive for FLI-1 and PRAME expression (85%). Malignant cells in 12 and 13 lymph nodes showed positive expression of PRAME and FLI-1, respectively. Only one case with a nevic cell deposit was weakly positive for FLI-1 and the remaining benign cases were negative for both FLI-1 and PRAME. Our results show that FLI-1/Melan-A dual stain is as sensitive and specific as PRAME in distinguishing lymph nodes with metastatic melanoma from nodal nevi. Further studies with larger case numbers are needed to support our significant results.
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
Coloring Agents
0
MART-1 Antigen
0
PRAME protein, human
0
MLANA protein, human
0
Proto-Oncogene Protein c-fli-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-258Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492. doi:10.3322/caac.21409
Patterson JW. Nevus cell aggregates in lymph nodes. Am J Clin Pathol. 2004;121(1):13-15. doi:10.1309/JXE9-EYQX-D691-LV2Y
Lezcano C, Pulitzer M, Moy AP, Hollmann TJ, Jungbluth AA, Busam KJ. Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. Am J Surg Pathol. 2020;44(4):503-508. doi:10.1097/PAS.0000000000001393
Torlakovic EE, Slipicevic A, Florenes VA, Chibbar R, DeCoteau JF, Bilalovic N. Fli-1 expression in malignant melanoma. Histol Histopathol. 2008;23(11):1309-1314. doi:10.14670/HH-23.1309
Zhang XK, Moussa O, LaRue A, et al. The transcription factor Fli-1 modulates marginal zone and follicular B cell development in mice. J Immunol. 2008;181(3):1644-1654. doi:10.4049/jimmunol.181.3.1644
Folpe AL, Chand EM, Goldblum JR, Weiss SW. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol. 2001;25(8):1061-1066. doi:10.1097/00000478-200108000-00011
Ramani N, Aung PP, Hwu WJ, et al. Aberrant expression of FLI-1 in melanoma. J Cutan Pathol. 2017;44(9):790-793. doi:10.1111/cup.12979
Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. PRAME expression in melanocytic tumors. Am J Surg Pathol. 2018;42(11):1456-1465. doi:10.1097/PAS.0000000000001134
Lee CK, Lin H, Su CF, Kok VC. Primary vaginal melanoma with rhabdoid features: a case report and literature review. Int J Gynecol Pathol. 2017;36(5):499-504. doi:10.1097/PGP.0000000000000354
Ashraf MJ, Beigomi L, Azarpira N, et al. The small round blue cell tumors of the sinonasal area: histological and immunohistochemical findings. Iran Red Crescent Med J. 2013;15(6):455-461. doi:10.5812/ircmj.4735
Rossi S, Orvieto E, Furlanetto A, Laurino L, Ninfo V, Dei Tos AP. Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod Pathol. 2004;17(5):547-552. doi:10.1038/modpathol.3800065
Strickler AG, Schaefer JT, Slingluff CL Jr, Wick MR. Immunolabeling for p16, WT1, and Fli-1 in the assignment of growth phase for cutaneous melanomas. Am J Dermatopathol. 2014;36(9):718-722. doi:10.1097/DAD.0000000000000066
Weissinger SE, Keil P, Silvers DN, et al. A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma. Mod Pathol. 2014;27(4):524-534. doi:10.1038/modpathol.2013.162
See SHC, Finkelman BS, Yeldandi AV. The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma. Pathol Res Pract. 2020;216(9):153105. doi:10.1016/j.prp.2020.153105
Koh SS, Wei JP, Li X, et al. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Mod Pathol. 2012;25(6):828-837. doi:10.1038/modpathol.2012.32